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Abstract: Progressive destruction of neurons that produce dopamine in the basal ganglia of the 
brain, particularly the substantia nigra, is a hallmark of Parkinson’s disease. The syndrome of the 
Parkinsonian phenotype is caused by many etiologies, involving multiple contributing   mechanisms. 
Characteristic findings are pathologic inclusions called Lewy bodies, which are   protein aggregates 
inside nerve cells. Environmental insults are linked with the disease, and a number of associated 
genes have also been identified. Neuroinflammation, microglia activation, oxidative stress, and 
mitochondrial dysfunction are central processes producing nerve damage. In addition, protein 
misfolding, driven by accumulation and condensation of α-synuclein,   compounded by inadequate 
elimination of defective protein through the   ubiquitin-proteasome system, promote apoptosis. 
Current pharmacologic therapy is palliative rather than   disease-modifying, and typically becomes 
unsatisfactory over time. Coenzyme Q10 and creatine, two agents involved in energy production, 
may be disease-modifying, and able to produce sufficient beneficial pathophysiologic changes 
in preclinical studies to warrant large studies now in progress. Use of long-chain omega-3 fatty 
acids and vitamin D in PD are also topics of current interest.
Keywords: Parkinson’s disease, mitochondria, inflammation, reactive oxygen species, apoptosis, 
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Introduction
Parkinson’s disease (PD), the second most common neurodegenerative disease, is 
a progressive movement disorder marked by rest tremor, slow muscle movement 
(  bradykinesia), rigidity of muscles, and postural instability. Although its prevalence 
in the US is presently about 1%–2% in people over 60 years of age, numbers will rise 
as the proportion of elderly in the population increases. Most symptoms are due to 
loss of specific dopamine-releasing neurons in the substantia nigra and pars compacta 
of the brain. Dopamine replacement helps relieve motor symptoms and as such, is 
successful as palliative therapy. Progress in treatment has been unsatisfactory, simply 
because there are no disease-modifying agents that are effective.
Delaying the degeneration of dopaminergic neurons essentially means slowing 
disease progression. Most recently, there has been intense interest in two agents, 
ubiquinone, also known as coenzyme Q10 (CoQ10) and creatine, which may have 
potential disease-modifying properties.
Targeting mitochondrial dysfunction with therapeutic agents in PD and other 
diseases is relatively new. Because mitochondria are involved in the pathogenesis of 
many illnesses, the concept is already finding wide application.Clinical Pharmacology: Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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Causes
A number of etiologies of PD have been identified,1 and a 
  complex cascade of interrelated molecular events is   beginning to 
unravel. Because more than one factor may contribute over the 
protracted course of the illness, the term   Parkinson’s   syndrome 
may be preferable. Current “causes” include genetic and 
  environmental factors, with common mediating   mechanisms of 
reactive oxygen species (ROS),   inflammation, and mitochon-
drial dysfunction playing a central role. An   introductory discus-
sion of factors involved in causes of Parkinson’s   syndrome helps 
to place the role of nutrients in perspective.
Genetic factors
Parkin is a protein that participates in the ubiquitin-protease 
system, and mutations in the encoding gene, PARK2, are among 
the genetic causes of PD. Even though about 11 “PARK genes” 
associated with Parkinson’s disease have been identified, and 
over 570 other genes are known to function abnormally, less 
than 10% of PD occurs on a genetic basis.2 Among several 
reported mutations, one in the gene coding for α-synuclein 
results in substitution of an alanine moiety for threonine at the 
PD-1 focus on chromosome 4q21–q23.3 The 140-amino acid 
residue protein α-synuclein, which plays a role in dopamine 
neurotransmission during its storage in vesicles,4 is natively 
unfolded but normally monomeric and soluble. It may mis-
fold and undergo changes which render it insoluble, and/or 
  oligomerize at high   concentrations.   Protofibrils, β-pleated 
sheets composed of fibrils, are   putative cytotoxic intermediates. 
Aggregation residues of the protein may become deposited in 
Lewy bodies, which are the   cardinal pathologic findings in PD. 
These bodies also contain   products of the ubiquitin-proteasome 
pathway, a protein disposal system in cells.
environmental
Environmental variables account for 90% of PD cases, 
with pesticides, herbicides, consumption of well water, and 
some microbes implicated in PD.5,6 Maneb and paraquat 
are   pesticides that are particularly troublesome.7 Rural 
  residence and   agricultural occupation is linked to higher risk. 
  Manganese exposure may speed progression of PD.8 While 
it has been amply demonstrated that non-heme iron raises 
the PD risk by up to 30%,9 ferritin within the neuromelanin 
granules of the substantia nigra and ferrous ion may lead to 
necrosis of cells.10,11
Mitochondrial dysfunction
The current view of mitochondria has changed sig-
nificantly from the older view of simple high-energy 
phosphate bond synthesis. The electron transport chain within 
the inner mitochondrial membrane essentially transfers 
electrons in food to oxygen, capturing and storing energy in 
adenosine triphosphate (ATP). In so doing, ROS are released 
as a   proton gradient is created across the mitochondrial 
  membrane. Mitochondria are both a source and a sink for 
ROS. CoQ10 (ubiquinone) is an essential component of three 
of four   mitochondrial complexes along the electron transport 
chain and is also a potent antioxidant. Mitochondrial DNA 
  transcription, and subsequently oxidative phosphorylation, 
may be regulated by the cell’s physiologic needs.   Conversely, 
mitochondria participate in several signaling loops that control 
transcription and cellular DNA transcription. The interaction 
between genetic and epigenetic signaling and mitochondria 
is complex. Apoptosis, or programmed cell death, follows 
a sudden event called mitochondrial   permeability transition 
(MPT), when opening of transition pores allows the passage 
of larger molecules through the mitochondrial membrane. 
Hence, they are called the “gates of survival”.
Considerable evidence now links mitochondrial dysfunc-
tion and PD, partially unifying the different “causes” pro-
posed. One hypothesis is that a selective defect in complex I 
of the electron transport chain in the mitochondria of cells 
in the substantia nigra, involving functionally impaired and 
misassembled subunits, may lead to an apoptotic cascade 
and PD.12 Properties of maternal polymorphic mitochondrial 
DNA may contribute to an age-related decline in mitochon-
drial dysfunction,13 and complex analysis of mitochondrial 
genetics further supports this notion.14 An imbalance of 
mitochondrial fission and fusion,15 or even poor remodeling 
of the inner membrane, may contribute to the disease pro-
cess.16 Recently, work using multinuclear magnetic resonance 
spectroscopy in PD reveals metabolic changes consistent with 
mitochondrial dysfunction.17
In evaluating both nutritional therapeutic changes and 
pharmacologic agents, studies are hampered by the sporadic 
nature of PD, which mandate large numbers of patients for 
statistical significance. In addition, the nutrients involved are 
not patentable, which requires special funding for trials. For-
tunately, encouraging preliminary reports have led to support 
of two large Phase III trials involving CoQ10 and creatine 
by the National Institutes of Health in the US.
Inflammation
Complement activation and raised secretion of proinflam-
matory cytokines and chemokines have suggested that 
  inflammation is involved in the pathogenesis of PD.18,19 Brain 
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in the development of PD. These cells mediate innate immune 
responses, function as scavenger cells, express cytokines, and 
modulate histocompatibility genes. Tumor necrosis factor-α, 
interleukins (IL)1β, 6, 2, and 4, prostaglandins (E2, J2), nitric 
oxide, inducible nitric oxide synthase, and other molecules 
released from immune and dying cells mediate the demise 
of cells in the substantia nigra which release   dopamine. 
  Neuroinflammation, now the basis for recent models of PD,20,21 
remains an attractive therapeutic target.22
Reactive oxygen species
Oxidative stress exists when the amounts of ROS and   reactive 
nitrogen species (RNS), such as peroxynitrites, exceed 
the antioxidant mechanisms that are available in the body. 
The source of these molecules is primarily from activated 
inflammatory and immune cells, specifically from microglial 
nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase activity and mitochondria. Phagocytic NADPH 
oxidase (NOX) comprises at least six components, ie, the 
plasma membrane-spanning cytochrome b558 (composed 
of gp91phox and p22phox), three cytosolic components 
(p67phox, p47phox, and p40phox), and rac, a small G 
protein. Experimental models of PD suggest that NOX is 
responsible for nerve cell degeneration.23 Preclinical models 
of PD confirm that such hyperreactive molecules are linked 
with the death of dopaminergic cells.24 ROS also amplify 
the release of cytokines, such as tumor necrosis factor-α, to 
increase nerve cell destruction. Mitochondrial antioxidants 
have been of intense investigative interest25 to thwart this 
destructive pathway. The relationships between mitochondrial 
dysfunction, the vulnerability of substantial nigra cells to 
stressors, and L-type Cav1.3 Ca2+ channels that drive their 
rhythmic pacemaking activity26,27 are unknown.
Protein accumulation
Cellular control of protein quality involves removal of 
abnormal proteins by the ubiquitin-proteasome system and 
prevents protein accumulation from damaging the cell.28 The 
classic example, α-synuclein- and ubiquitin-positive inclusion 
bodies, are the pathologic hallmarks of PD, and a defective 
ubiquitin-protease system has been thought to contribute to 
their accumulation. Proteasomal degradation through the 
ubiquination-protease system produces polyubiquinated pro-
teins, whereas ubiquitinated α-synuclein found in Lewy bodies 
in surviving substantia nigra nerve cells are mono- and diubiq-
uitinated forms.24 Such proteins may result from environmental 
factors and toxins, genetic mutations, and errors in transcription, 
translation, and/or protein   folding. Misfolding of proteins and 
failure to remove defective   proteins are intimately associated 
with the pathogenesis of PD. The ubiquitin-proteasome path-
way may be overwhelmed or malfunction in PD.29 Excessive 
amounts of aggregated and changed forms of α-synuclein also 
raise levels of ROS and participate in mitochondrial dysfunc-
tion.30 Promotion of correct protein folding and facilitating 
removal of harmful proteins with agents such as heat shock 
proteins are potentially fertile areas for future investigation.
excitotoxicity
Microglia, once activated, secrete another class of neurotoxic 
agents, ie, excitotoxins, which overstimulate the receptors for 
glutamate, an excitatory neurotransmitter, allowing excessive 
amounts of calcium to enter nerve cells. Glutamate accumu-
lation promotes development of RNS, calcium-mediated 
mitochondrial damage, and resulting apoptosis in neurons.
The etiologies, mechanisms of pathogenesis in dop-
aminergic cell death, and potential therapeutic targets are 
summarized in Table 1.
Creatine
Creatine, chemically known as α-methyl-guanidinoacetic 
acid, is a naturally occurring nitrogenous organic acid which 
is produced endogenously, and is also ingested in food. About 
half of total body creatine is derived from dietary meat, with 
the remainder synthesized in the liver and pancreas from 
glycine, methionine, arginine, and two enzymes. Since these 
two enzymes are not concentrated within the same organ, 
synthesis begins in the kidney and is completed by methylation 
in the liver. The largest amount of creatine is found in skeletal 
muscle, followed by cardiac muscle, and these are tissues that 
do not synthesize creatine significantly. Regulation of endog-
enous synthesis most likely occurs at a pretranslational level.31 
Creatine synthesis may be a more significant process than 
previously believed, with an important influence upon amino 
acid metabolism.32,33 Because of the intermetabolic involve-
ment of methionine and homocysteine, methyl donor balance is 
also affected.33 Approximately 1.7% of the total creatine pool 
is excreted daily in the form of urinary creatinine.
Well known because it is used as an ergogenic aid by 
athletes and bodybuilders to increase strength and muscle 
mass, creatine is not only a storage depot of energy,34 but may 
also facilitate recovery after exercise35,36 and promote muscle 
repair.36 The reaction of primary interest in which creatine 
participates is phosphorylation by the enzyme creatine kinase 
to form phosphocreatine in mitochondria (Figure 1).
Since the reaction is reversible, phosphocreatine serves 
as an energy buffer when high-energy phosphate is needed. Clinical Pharmacology: Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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In addition, creatine/phosphocreatine facilitates energy 
transfer by diffusing from mitochondria, where ATP is syn-
thesized, to other cellular locations where ATP is utilized, 
and stabilizes ATP synthesis. Creatine also modulates the 
adenosine diphosphate (ADP) ATP ratio, so ATPase function 
is not unduly inhibited. The supportive action of creatine 
on energy transduction has led to its hypothetical role as an 
indirect antioxidant in preventing mitochondrial permeability 
transition.27,38
A transporter is responsible for creatine uptake into muscle, 
kidney, and brain, and appears to be a member of the sodium-
dependent neurotransmitter transporter family. Transportation 
occurs against a substantial creatine gradient and is driven by 
sodium-potassium-ATPase.39 Creatine is not synthesized in 
the brain, but is made in glial cells. Neurons receive creatine 
slowly from nearby glia and from the blood via the creatine 
transporter. The function of a creatine transporter in mitochon-
drial membranes has not been well characterized.
Creatine not only increases muscle strength in healthy 
athletes, but may also do so when muscle strength is 
reduced as a result of disease. In both preclinical studies 
and in patients, oral creatine has been shown to increase 
strength in neuromuscular disorders,40 including the mus-
cular dystrophies.41 Beneficial effects on muscular strength 
has also been reported in patients with heart failure,42,43 
and in the elderly suffering from sarcopenia,44,45 ie, loss of 
muscle mass in which both inflammation and mitochondrial 
dysfunction are evident. Muscle mass and strength lost 
during immobilization may also be preserved by creatine 
administration.46
Creatine effect on cognition and neuroprotection
The important role creatine plays in energy metabolism in 
nerve tissue and brain physiology is less well appreciated than 
its muscular effects. Severe brain creatine/phosphocreatine 
deficiency resulting from an inborn error of metabolism 
is characterized by mental retardation, striking language 
impairment, autistic-like behavior, movement disorders, 
and/or seizures.47,48 Such syndromes are partially reversible 
with creatine replacement therapy.
Table 1 Summary of factors and approaches in the pathogenesis of Parkinson’s disease
etiology Genetic
environmental
Genetic susceptibility to environmental factors
Mechanisms in pathogenesis Inflammation
Mitochondrial dysfunction
Oxidative and nitrosative stress
Accumulation of proteins/defective protein clearance
excitotoxicity
Loss of neurotrophic factors
Mechanisms of dopaminergic cell death Loss of mitochondrial membrane potential
Mitochondrial permeability transition
Loss of cytochrome c from mitochondria
Accumulation of cytosolic calcium
Activation of apoptotic pathways
Therapeutic classifications and potential targets Anti-inflammatory
Mitochondrial (coenzyme Q10, Carnitine, uncoupling protein 2 expression)
excitotoxicity (antiglutamate)
Calcium overload (calcium channel blockers)
Protein accumulation (heat shock proteins, proteasomal enhancers)
Antiapoptotic stabilizers
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Figure 1 Phosphorylation of creatine by creatine kinase to form phosphocreatine in mitochondria.Clinical Pharmacology: Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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Due to a relative lack of dietary meat, vegetarians and 
vegans generally have low creatine intakes. A double-blind, 
placebo-controlled, crossover trial in 45 such individuals 
was conducted by supplementing with creatine monohydrate 
5 g/day. Creatine was found to improve nonverbal intelli-
gence, verbal memory capacity, and short-term memory.49
Sleep deprivation has a negative effect upon cognition, 
psychomotor performance, and mood, and is in part due 
to depletion of brain creatine.50 In a double-blind study 
of 19 sleep-deprived subjects, tests of random movement 
  generation, verbal and spatial recall, choice reaction time, 
static balance, and mood state were done with and without 
administration of creatine 20 g/day, during progressively 
greater sleep deprivation. After sleep deprivation for 
24 hours, creatine had a positive effect on mood state and 
tasks that placed a heavy demand on the prefrontal cortex.50 
Further work by the same group extended and confirmed 
similar improvement in multiple tests of cognitive function 
using creatine 20 g/day in the elderly.51
In laboratory models of spinal cord injury,52,53 and after 
experimental traumatic brain injury,54 creatine either pro-
tected against cell damage or assisted in recovery. Similarly, 
creatine affords protection in mouse models of stroke.55,56 In 
one study, creatine supplementation for three weeks followed 
by a 45-minute ligation of the middle cerebral artery reduced 
the amount of brain tissue lost by about 40%.57 No significant 
changes in creatine/phosphocreatine were identified. In other 
preparations, however, creatine was capable of attenuating 
decreases in energy-containing phosphocreatine and ATP 
in anoxic brain tissue, and reduced nerve damage caused by 
excitotoxins and malonate.58
Creatine is also neuroprotective in animal models of 
amyotrophic lateral sclerosis59 and in Huntington’s disease.60 
Benefits of creatine in human patients,61 including reductions 
in markers of oxidative injury to DNA,62 have been sufficient 
to warrant a Phase III trial sponsored by the National Insti-
tutes of Health. Huntington’s disease is an incurable neuro-
degenerative disease in which there is abnormal movement 
and marked loss of nerve cells. Huntington’s disease shares 
pathogenetic similarities with PD, including aberrant protein 
deposition, oxidative damage, and mitochondrial dysfunc-
tion, all in association with an intracellular energy crisis.
Taken together, the selected studies mentioned above 
indicate creatine is capable of neuroprotection in a variety 
of situations in which either depletion of phosphocreatine or 
metabolic stress produces nerve cell death.
A rodent model of PD is produced by using 1-methyl 
4-phenyl 1,2,3,6-tetrahydropyridine (MPTP), which   produces 
a loss of about 30% of the cells that secrete dopamine in the 
substantia nigra. In this model, creatine protects against both 
neuron and dopamine loss in a dose-dependent manner.58,63
Some recent basic science correlates of these   observations 
help us to understand and unite the actions of different agents 
into a cohesive working model. First, creatine has direct 
antioxidant actions against both reactive oxygen and nitrogen 
species, including the destructive superoxide and peroxyni-
trite moieties.64 Given the critical role of oxidative stress in 
producing neurodegeneration in PD and related conditions, 
the antioxidant effects of creatine may be a mechanism of 
action,59 but what is a cause and what is an effect remains 
unknown.65
Second, unique subcellular spatial locations of mitochon-
drial creatine kinase have been described that expand our 
understanding of the role of the creatine/phosphocreatine-
creatine kinase system. Mitochondria have inner and outer 
membranes which make contact at discrete points.66 It is 
believed that a “microcompartment” exists at those points 
ensuring that, if creatine is available, ATP efficiently   converts 
to phosphocreatine.37,67 The resulting high   concentration 
of ADP helps stabilize mitochondrial transition pores, 
  decreasing the probability of MPT and cell death.
This action is important because a number of other 
coexisting factors tend to raise the probability of MPT, 
including loss of CoQ10 from the electron transport chain, 
sluggish oxidative phosphorylation, loss of mitochondrial 
membrane potential, oxidative stress, and increased calcium 
flux. MPT may be accompanied by further loss of membrane 
potential and leakage of proapoptotic molecules, such as 
cytochrome c, out of the mitochondria. One apoptotic cas-
cade involves members of the Bcl-2 family, proteins that are 
either pro- or antiapoptotic, with consequent activation of 
caspases that trigger apoptosis and subsequent cell death.68,69 
Phosphocreatine also functions to ensure sufficient energy 
so calcium pumps may prevent local rises in calcium con-
centrations, which may itself promote apoptosis.70 One can 
easily appreciate how delicate the balance of multiple forces 
upon mitochondria may be, ultimately determining the fate 
of vulnerable nerve cells which are critical in the production 
of dopamine. While it has been thought that many of the 
salutary effects of creatine are related to energy transduction, 
a component may in fact be energy-independent.71
Phase ii and Phase iii studies
After a small initial trial of creatine in PD patients established 
its safety, a randomized double-blind, Phase II futility study 
assessed the effect of creatine 10 g/day and minocycline Clinical Pharmacology: Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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on the clinical course of early PD.72 In this study, using a 
  predetermined “futility” threshold, creatine lowered the total 
Unified Parkinson’s Disease Rating Scale (UPDRS) score 
from the onset of treatment to 12 months or when   standard 
medical therapy was needed (whichever came first). The 
futility threshold assigned was a 30% reduction in UPDRS 
score progression, taken from the control group of the Depre-
nyl and Tocopherol Antioxidative Therapy of   Parkinsonism 
(DATATOP) trial.73 Creatine could not be rejected as futile 
based upon the UPDRS score needed to qualify, and was 
tolerated well. After a year, PD progression was delayed by 
nearly 50%, as judged by UPDRS scores.72
Following this, the National Institute of Neurological 
Disorders and Stroke announced a Phase III clinical trial ran-
domizing 1720 early-stage PD patients to creatine 10 g/day 
or placebo.74,75 The study will last about 5–7 years and be 
conducted at 52 medical facilities.
Creatine is well absorbed, bioavailable, and safe. In one 
study, a creatine dose of 20 g/day was given to PD patients 
along with resistance training.76 Muscular endurance and 
upper body strength improved. Side effects of creatine 
include gastrointestinal symptoms, muscle cramps, and an 
increase in intracellular water because of the osmotic load 
imposed by additional creatine.
Coenzyme Q10 (ubiquinone)
CoQ10 (ubiquinone) is a lipid-soluble benzoquinol with 
a side chain of 10 isoprenoid units (Figure 2). Of the total 
CoQ10 plasma pool, 60% is endogenous,77 and the remainder 
comes from ingested CoQ10 or its precursors. In vivo, about 
95% is found as the reduced form, ie, ubiquinol. CoQ10 is 
best known for its role in the inner mitochondrial membrane 
that shuttles electrons in the electron transport chain from 
complexes I and II to complex III (Figure 3).78
Because of its relatively small size, CoQ10 is able to 
diffuse within the lipid bilayer of the inner mitochondrial 
membrane between fixed electron carriers. It is therefore 
essential for oxidative phosphorylation, and subopti-
mal CoQ10 concentrations within the respiratory chain 
  complexes impede the development of a protein gradi-
ent across the mitochondrial inner membrane, resulting 
in defective production of ATP. Intramembrane CoQ10 
levels are therefore rate-limiting. CoQ10 deficiency also 
predisposes to MPT, leading to apoptosis. It also serves as 
a cofactor for   uncoupling proteins and other mitochondrial 
  dehydrogenases, as a regulator of extracellularly-induced 
ceramide-dependent apoptotic pathways,79 and as a regula-
tor of the MPT pore. CoQ10 is also an effective antioxidant 
that is a free radical scavenger in intracellular organelle 
membranes, and is an important antioxidant that travels in 
lipoproteins, affording partial protection against oxidation of 
low-density lipoprotein.80 CoQ10 levels decrease with age, in 
chronic disease, and as a side effect of certain pharmacologic 
agents, especially statins.
Evidence implicating mitochondrial dysfunction in PD is 
now undeniable.14,17,81 As mentioned, MTPT is toxic to com-
plex I in the mitochondria and mimics Parkinson’s syndrome 
in several species, including man.82 Rotenone, a pesticide and 
neurotoxin, also inhibits complex I.83 It has been implicated 
in PD cases and interestingly, activates microglia, leading to 
destruction of those neurons that produce dopamine.84,85
Platelet mitochondria in untreated PD patients show low 
complex I and II/III activity,86 and complex I activity is also 
low in the substantia nigra of PD patients.87 A novel method 
of studying complex I activity and apoptosis in mitochon-
dria from PD patients confirmed that complex I is indeed 
depressed, in association with lower ATP and cytochrome c 
concentrations, depolarization of membranes, and greater 
caspase 3 activity, a key step in one apoptotic pathway.88 
Hence, in this preparation, defective oxidative phosphoryla-
tion resulting from complex I pathology appears to be linked 
to enhancement of apoptotic pathways in PD.
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Figure 2 The structures of ubiquinone (top) and ubiquinol (bottom). Ubiquinone, the 
oxidized (benzoquinone form of the pair, is 2,3-dimethoxy-5-methyl-6-decaprenyl-
1,4-benzoquinone. its isoprenoid group (CH3-CH=C(CH3)-CH3) is repeated 10 times 
in the side chain. Ubiquinol, the reduced (hydroxyl groups at positions 1 and 4 on 
the benzene ring) form, less two electrons, is 2,3 dimethoxy-5-methyl-6-decaprenyl-
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CoQ10 levels are nearly one-third lower in platelet 
  mitochondria from PD patients than in age- and gender-
matched controls, and levels in serum and some organs fall 
faster in PD patients during aging as well.89 Furthermore, 
the proportion of CoQ10 in its oxidized form is higher in PD 
patients, linking oxidative stress with disease pathogenesis.
Orally administered CoQ10 reduced the loss of dop-
amine and the nerves that produce it in the substantia nigra 
of MTPT-treated mice.90 CoQ10 is neuroprotective against 
damage mediated by malate and excitotoxins.91,92 Rotenone-
induced loss of dopaminergic neurons is also attenuated by 
CoQ10 pretreatment.93,94 As a result of findings in a primate 
model of PD, activation of uncoupling protein 2, leading to 
preservation of mitochondrial membrane potential and ATP 
production, was postulated to be one mechanism of CoQ10 
protection.95 However, binding sites for CoQ10 that regulate 
the permeability transition pore have been identified within 
complex I in mitochondria, and therefore protection may 
also be afforded in PD because of the antiapoptotic effect 
of MPT pore stabilization.
Studies using magnetic resonance spectroscopy have 
documented raised cerebral lactate levels and metabolic 
changes that suggest depressed aerobic and greater anaerobic 
metabolism in PD patients.17,96 Using anatomic magnetic 
resonance imaging combined with phosphorus and proton 
magnetic resonance spectroscopic imaging, low levels of 
both ATP and phosphocreatine in the midbrain of PD patients 
were found.97 This constitutes hard evidence in vivo that 
mitochondrial dysfunction and defective oxidative phospho-
rylation are involved in PD.
An early study of CoQ10 administration to patients 
  produced no symptomatic improvement but did raise 
complex I activity.98 A Phase II study (QE2) to evaluate safety 
and tolerability, but not neuroprotection or efficacy, of CoQ10 
300–1200 mg was undertaken in 80 PD patients.99 There was 
a statistically meaningful difference between those receiving 
1200 mg and 300 mg, as measured by the UPDRS. Slower dete-
rioration was noted in all three sections of the UPDRS (Part 1, 
mentation, behavior and mood; Part 2, activities of daily   living; 
and Part 3, motor examination). The higher dose of CoQ10 
produced greater activity of the electron transport chain.
A futility trial using CoQ10 2400 mg randomized 
71 patients with early untreated PD for one year. The mean 
change in UPDRS, compared with a prespecified threshold 
Figure 3 electrons move from food to Krebs cycle intermediates, in a series of oxidation-reduction reactions as they are shuttled through complexes i through iv of 
the respiratory chain, eventually reaching oxygen. The electron transport chain effecting oxidative phosphorylation is composed of fixed multimeric protein complexes I 
through v, each with multiple subunits, along the inner mitochondrial membrane, along with two electron carriers, ie, ubiquinone and cytochrome c. As electrons move 
along the oxidation-reduction complexes i–iv, protons are pumped from the matrix to the intermembrane space by complexes i, iii, and iv, creating a proton [H+] gradient 
across the mitochondrial inner membrane. As the protons return to the intermembrane space through complex v (far right, labeled ATP synthase), dissipating the gradient, 
changes in conformations of enzyme F1F0 ATP synthase, which spans the membrane, produce ATP. The inner mitochondrial membrane must remain impermeable to [H+] in 
order to sustain the gradient, which uses about 15% of the total metabolic rate of working tissue.
Reproduced with permission of Mariana Ruiz villarreal, via wikipedia commons.
Abbreviations: CoQ, Coenzyme Q10 (ubiquinone); CoQH, reduced Coenzyme Q10 (ubiquinol); NAD, nicotinamide adenine dinucleotide; AT, adenosine triphosphate; 
AD, adenosine diphosphate; Cyt c, cytochrome c. Clinical Pharmacology: Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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from the DATATOP trial, was not found to be futile, and the 
authors concluded more research was warranted.100
Currently a Phase III efficacy (QE3) trial is   randomizing 
about 600 untreated patients to CoQ10 120 mg/day or 
2400 mg/day or placebo. Using the three parts of the UPDRS 
and other scales, function, cognition, and quality of life will 
be followed for 16 months and/or when symptomatic therapy 
becomes necessary. Plasma CoQ10 levels at months 1, 8, and 
16 are included in the protocol.101
The number of CoQ10 products and processing efforts 
to increase CoQ10 absorption is bewildering, and the abil-
ity of products to raise CoQ10 levels varies considerably. 
  Ubiquinone has been supplied in various forms, charac-
teristically with poor absorption. Ubiquinol, the oxidized 
form, and/or solubilized forms, are better absorbed and are 
preferred when older or ill populations are being treated. 
Monitoring CoQ10 levels is desirable to assure adequate 
blood levels, since the large amounts of CoQ10 prescribed 
and the expense may impair adherence.
Long-chain omega-3 
polyunsaturated fatty acids
Due to both overconsumption of omega-6 fats and undercon-
sumption of omega-3 fats, the typical Western diet contains an 
omega-6/omega-3 ratio of about 20:1, with the ideal estimated 
between 1–3:1. This is unfortunate, given that a higher intake 
of omega-3 polyunsaturated fatty acids (PUFA) is associ-
ated with low all-cause mortality.102 Omega-3 fats constitute 
over 50% of brain weight. Of the two major active PUFA, 
eicosapentaenoic acid (EPA) is regarded as the more anti-
inflammatory, with docosahexaenoic acid (DHA) more likely 
to be incorporated into membranes and act through derivatives 
called resolvins and neuroprotectins. While the recommended 
amount of DHA is about 200–300 mg/day, the typical intake 
ranges from 60–80 mg/day. Up to 60% of the fatty acids 
esterified in neuronal membrane phospholipid are DHA. 
In the elderly, total intake of omega-3 PUFA is generally 
poor,103 while robust consumption is associated with improved 
  cognitive function.104–107
Epidemiologic studies suggest that high intake of 
  omega-3 PUFA may reduce the risk of PD, while acute stud-
ies in animal models of PD also suggest a more immediate 
neuroprotective effect. In the Rotterdam study, over 5000 
subjects completed a food frequency questionnaire and were 
followed for six years.108 Both dietary omega-3 PUFA and 
monounsaturated fatty acids were associated with a signifi-
cantly reduced risk of PD. No link was noted with either 
omega-6 PUFA or DHA intake.
In two other large prospective studies, there was no 
association between omega-3 PUFA and PD risk.109 However, 
when total PUFA in the diet was replaced isocalorically with 
saturated fat, the risk of PD rose. A recent analysis of diet 
in the same cohort showed an inverse association of PD risk 
with intake of fish, fruit, and vegetables.110
In monkeys who received MPTP to induce PD-type 
lesions, DHA was found to protect against dyskinesias 
(abnormal movements) induced by levodopa.111 In fact, DHA 
appeared to lower the severity, or delay the appearance of 
the motor movements arising as complications of levodopa 
therapy. These results are important because they indicate 
omega-3 PUFA are capable of potentially modifying the 
course of the pathogenesis of complications of an animal 
equivalent of PD.
In a mouse model of PD, animals were maintained on 
either a control diet, conventionally high in omega-6 fats, or 
another diet high in omega-3 fats, followed by administration 
of MPTP.112,113 In the high omega-3 diet group, mice suffered 
no loss of dopamine or dopaminergic neuron death after 
MPTP was given. In contrast, mice consuming the “control” 
(Western) diet manifested loss of nigral nerve cells that pro-
duce dopamine, with dopamine secretion decreased by half. 
This study clearly shows that high omega-3 PUFA has a 
powerful neuroprotective effect in the murine model of PD.
MPTP, after injection, may lead to activation of micro-
glia, with a consequent rise in interleukins 1β and 6. Deletion 
of COX-2 enzymes, or pharmacologic inhibition of COX-2, 
diminishes MPTP toxicity, supporting a strong inflammatory 
component in the events involved in the MPTP-induced dam-
age typical of PD. Indeed, some authors have hypothesized 
that DHA incorporates into and displaces proinflammatory 
omega-6 fats in neurons and mitochondria of the substantia 
nigra114 to attenuate the harmful actions of MPTP. Quelling of 
oxidative and mitochondrial DNA damage by DHA is postu-
lated as another mechanism.115 DHA also changes membrane 
structure,116 signal transduction,117 and voltage-dependent 
calcium channels in nerves,118 which is of particular interest 
in view of the calcium channel-related hypothesis concerning 
destruction of neurons in PD.27 Last, DHA modulates intra-
cellular calcium and may protect against caspase-mediated 
apoptosis.119 The mechanisms of these protective effects in 
laboratory models are noteworthy, because they parallel those 
operative in the human clinical syndrome.
Omega-3 PUFA modulate inflammation,116,120 may 
inhibit generation of ROS,121 and modify signaling in lipid 
rafts.106 DHA in membranes are released by phospholipase, 
and derivative molecules such as neuroprotectin D1 have Clinical Pharmacology: Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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pleiotropic neurotrophic properties, including promotion of 
antiapoptotic proteins in the Bcl-2 family, as well as potent 
anti-inflammatory actions. Another property of potential 
significance in PD, in which protein misfolding has been 
the subject of intense interest, is the ability of   neuroprotectin 
D1 to prevent misfolding and forestall cell death.122 The 
multimechanistic neuroprotection afforded by DHA has only 
recently been appreciated in the biology of   neurodegenerative 
diseases.
Inefficient metabolic pathways exist for elongation of the 
18-carbon α-linolenic acid to EPA and DHA. In older adults, 
conversion of α-linolenic acid to DHA is quite limited, with 
better yields for EPA.123 There is doubt that conversion, occur-
ring chiefly in the liver, under the best of circumstances, can 
alone furnish sufficient DHA for optimal neurologic health.124 
Therefore, these omega-3 PUFA requirements should be 
met by using the long chains themselves, EPA and DHA, 
rather than through plant sources rich in α-linolenic acid, 
the most popular being flax.
Vitamin D
Calcitriol (1,25-dihydroxyvitamin D) is more of a 
  secosteroid hormone than “a vitamin”, and vitamin D 
receptors are plentiful in brain neurons and glia.125 As in 
most tissues, vitamin D receptors regulate genomic and 
metabolic signaling in nerve cells. Vitamin D helps control 
neurotrophin turnover, glutathione synthesis, inducible 
nitric oxide synthase activity, and apoptosis, all of which 
are pertinent to the pathogenesis of PD. Vitamin D also has 
immunomodulatory and neuroprotective effects in brain 
tissue. The benefit of maintaining optimal vitamin D levels 
in the elderly receiving home care, or confined to a nursing 
home, has received considerable recent attention, and is part 
of a growing realization that vitamin D deficiency is in fact 
a major public health issue.
A relatively high prevalence of vitamin D deficiency and 
low bone mass in PD has been known for some time.126 In 
one study, 55% of patients with PD, 41% with Alzheimer’s, 
and 36% of controls were vitamin D deficient, with more 
PD patients being markedly deficient.127 Moreover, cognitive 
function, impaired in about 40% of PD patients, is   dependent 
upon adequate vitamin D levels in older men.128 In the elderly 
receiving home care, vitamin D deficiency (14.5%) and 
insufficiency (44.3%) were associated with a two-fold risk 
of dementia, stroke, and large vessel infarcts, suggesting that 
vitamin D deficiency also contributed to cerebrovascular 
disease.129 The presence of dementia in PD patients is an 
independent predictor of mortality.130
PD patients with low bone mass face an additional risk 
for fractures compared to their counterparts in the general 
population.131 Several randomized controlled trials have 
confirmed that vitamin D replacement in PD patients is bene-
ficial, safe, and warranted.132 Calcium and vitamin D 5000 IU 
daily can increase lumbar bone density up to 28% within 
a year in association with a lower incidence of   fractures.133 
A minimal amount of supplementary vitamin D 400 IU daily, 
may lower hip fractures by 18% and   nonvertebral fractures 
by 20%.134
Sarcopenia, ie, age-related decrease in muscle mass, 
is another potential consequence of hypovitaminosis D.135 
Muscle weakness (a prominent feature of severe clinical 
vitamin D deficiency), substandard physical performance, 
and increasing debility are predicted by poor vitamin D status 
in the elderly.136 These may be accompanied by pain, which 
is another debilitating factor. After treatment with vitamin D, 
binding of vitamin D to its receptor in muscle leading to 
de novo protein synthesis are events that occur earlier than 
  vitamin D benefits upon bone. Moreover, vitamin D replace-
ment may reverse such muscle impairment, and assists during 
rehabilitation to attain better outcomes.137 Vitamin D defi-
ciency may cause a skeletal muscle myopathy even without 
detectable bone involvement.138 By directly increasing muscle 
performance, vitamin D administration improves climbing 
ability and promotes physical activity.132
The constellation of postural instability (a common fea-
ture of PD), poor muscle strength, frailty, age-related comor-
bidities, and confusion create a perfect “storm” for falls in 
this population. Partial vitamin D replacement at 800 IU/day 
halves the rate of falls in older residents in facilities,139 an 
effect which qualitatively persists even in latitudes bathed by 
sunlight.140 Each year, one-third of people 65 years or older 
suffer a fall, with 9% of them visiting an emergency room and 
5%–6% sustaining a fracture. The consequences of falls and 
hip fractures are dire, with 50% having permanent functional 
disabilities, 20% or more requiring nursing home placement, 
and up to 20% dying within a year. Moreover, in the year 
after a fracture, 30% are readmitted for acute care.
A meta-analysis of eight randomized controlled trials 
examined the effect of vitamin D administration among 
older participants with or without calcium.134 At doses of 
700–1000 IU of vitamin D2 or D3, the risk of falls decreased 
by an average of 19%, with the greatest effect of vitamin D3 at 
26%. Amounts of less than 700 IU, or serum 25-OH-vitamin D 
levels of ,60 nmol/L did not lower the risk of falling. While 
added calcium and physiotherapy are believed to improve 
outcomes, the effects of ensuring adequate 25-OH-vitamin D Clinical Pharmacology: Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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blood levels at 50–75 nmol/L provides a relatively   inexpensive 
and simple method for potentially substantial rewards.
Forty-five patients living in a Romanian nursing home with 
a mean vitamin D level of 28.9 nmol/L were given vitamin D 
5000 IU and elemental calcium 320 mg (800 mg CaCO3) to 
assess the effects upon serum vitamin D level, bone density, 
parathyroid hormone, and fall rate.141 After three months, 
there was a 58% decline in parathyroid hormone, vitamin D 
level exceeded 74 in 92% of the patients, and at 12 months, 
the Z scores for bone mineral density at the lumbar spine and 
the hip both increased significantly. These data confirm that 
to improve low bone density, vitamin D blood levels must 
be at least higher than 72 nmol/L, and that at least 320 mg 
of elemental calcium must be added to the diet. The 5000 IU 
dose was found to be safe in this population, with no persist-
ing hypercalcemia or hypercalciuria.
Actual involvement of vitamin D in the pathogenesis of PD 
was proposed by Newmark and Newmark.142 In the first lon-
gitudinal study to evaluate the association between vitamin D 
and the risk of PD, Knekt and associates143 recently conducted 
a prospective study of 3,173 men and women as an extension 
to the Mini-Finland Health Survey. The enrollees, free from 
the disease at the beginning of the survey, were followed for 29 
years for the development of PD. Investigators found a signifi-
cant association between levels of serum 25-hydroxyvitamin 
D levels and the risk of developing PD after adjustment for 
sex, age, education, alcohol consumption, physical activity, 
smoking and body mass index. Those with the highest vita-
min levels (50 nmol/L) were 65% less likely to develop PD 
than those with the lowest levels (25 nmol/L). Even though 
the subjects were chronically deficient in vitamin D, since 
Finland has relatively low exposure to ultraviolet radiation, a 
dose-response relationship was still evident. In an accompany-
ing editorial, Evatt144 discussed the supporting neurobiology 
of vitamin D, especially the finding of 1-α-hydroxylase (the 
enzyme that converts inactive vitamin D2 to its active D3 form) 
and vitamin D receptors in the brain.125,145,146 Interestingly, at the 
same time another study appeared147 in which vitamin D was 
reported to protect against cognitive decline in elderly partici-
pants. Possible mechanisms for the neuroprotective effects in 
PD, presumably impeding the loss of dopaminergic neurons, 
include antioxidative properties, modulation of intraneuronal 
calcium concentrations, especially in relation to mitochondria, 
and improved immune function.148 Since vitamin D deficiency 
is common in the general population, and frequent in the 
elderly, especially patients with neurodegenerative diseases, 
prudent optimization of vitamin D levels has been suggested to 
lower PD risk, delay cognitive loss, and assist musculoskeletal 
function. To achieve such levels, amounts of up to ~8000 IU 
per day have been required, which necessitates careful moni-
toring, since this amount exceeds the 2000 IU recommended 
by Osteoporosis Canada and will also be higher than the 
anticipated new recommendation by the Institute of Medicine. 
Randomized clinical trials to confirm results of observational 
studies and delineate proper doses are needed.
Conclusion
“Mitochondrial therapy”, both preventive and immediate, is a 
relatively new concept, and inroads have been significant, not 
only in neurologic disease but also in the intensive care unit, 
and in cardiology, renal, and other medical disciplines. While 
advances in the clinical management of PD with drugs have 
improved the quality of life in patients dramatically in terms 
of symptoms, there are no disease-modifying agents available. 
Recent work suggests that inflammation, oxidative, and nitrosa-
tive stress, accumulation of abnormally folded and/or aggre-
gated proteins, and defects in the ubiquitin-proteasome system 
are central molecular events in the pathogenesis of familial and 
sporadic PD. The possible beneficial disease-modifying effects 
of CoQ10 and creatine are presented in the context of this cur-
rent molecular model. In view of the rapid and encouraging 
recent work concerning omega-3 fatty acids and vitamin D, 
their supportive practical role in targeted pharmaconutritional 
therapy of PD deserves clinical consideration. 
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